Drug maker Sanofi, Google’s life sciences team and the Joslin Diabetes Center, Boston, will collaborate in an effort to improve care and outcomes for people with type 1 and type 2 diabetes.
“It’s very encouraging to see healthcare and technology innovators step up to the challenge of providing cutting-edge tools and care advancing technologies to help people with diabetes manage their disease, 24/7,” said John L. Brooks III, president and CEO of the Joslin Diabetes Center. “Technology, sensors, analytics and digital solutions will revolutionize how blood sugars are managed, which will deliver improved quality of life, lowering the risk of complications and reducing the costs and barriers associated with diabetes care.”
Using Sanofi’s expertise in diabetes treatments and devices and Google’s expertise in analytics, miniaturized electronics and low power chip design, the two companies will try to develop new tools and interventions for the disease. These tools and interventions may relate to health indicators such as blood glucose and hemoglobin A1c levels and may include patient-reported information, medication regimens and sensor devices, the companies said in a press release.
“With new technologies emerging to provide a more continuous and real-time view of a patient’s health, we can see the promise for more proactive and effective ways to control diabetes,” said Andy Conrad, CEO of Google’s life sciences team. “Together with Sanofi, we believe diabetes management can be simpler and more convenient, which may help patients achieve an improved quality of life.”
Pascale Witz, executive vice president at Sanofi, will lead the Global Diabetes and Cardiovascular Care Business Unit in the company’s new organizational structure.
“The life sciences team at Google can help us improve the patient experience, outcomes and manage healthcare costs more effectively,” she said.
